DE69931178D1 - Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 - Google Patents

Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2

Info

Publication number
DE69931178D1
DE69931178D1 DE69931178T DE69931178T DE69931178D1 DE 69931178 D1 DE69931178 D1 DE 69931178D1 DE 69931178 T DE69931178 T DE 69931178T DE 69931178 T DE69931178 T DE 69931178T DE 69931178 D1 DE69931178 D1 DE 69931178D1
Authority
DE
Germany
Prior art keywords
virus
endothelic
vascular
activates
vegf receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69931178T
Other languages
English (en)
Other versions
DE69931178T8 (de
DE69931178T2 (de
Inventor
Lyn M Wise
Andrew A Mercer
Loreen J Savory
Stephen B Fleming
Steven A Stacker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
University of Otago
Ludwig Institute for Cancer Research New York
Original Assignee
Ludwig Institute for Cancer Research Ltd
University of Otago
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, University of Otago, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of DE69931178D1 publication Critical patent/DE69931178D1/de
Application granted granted Critical
Publication of DE69931178T2 publication Critical patent/DE69931178T2/de
Publication of DE69931178T8 publication Critical patent/DE69931178T8/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69931178T 1998-11-02 1999-11-02 Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2 Active DE69931178T8 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10668998P 1998-11-02 1998-11-02
US106689P 1998-11-02
US10680098P 1998-11-03 1998-11-03
US106800P 1998-11-03
PCT/US1999/025869 WO2000025805A1 (en) 1998-11-02 1999-11-02 Vascular endothelial growth factor-like protein from orf virus nz2 binds and activates mammalian vegf receptor-2

Publications (3)

Publication Number Publication Date
DE69931178D1 true DE69931178D1 (de) 2006-06-08
DE69931178T2 DE69931178T2 (de) 2007-02-22
DE69931178T8 DE69931178T8 (de) 2007-06-28

Family

ID=26803915

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69931178T Active DE69931178T8 (de) 1998-11-02 1999-11-02 Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2

Country Status (8)

Country Link
US (2) US6541008B1 (de)
EP (1) EP1126863B1 (de)
JP (1) JP2003517275A (de)
AT (1) ATE324902T1 (de)
AU (1) AU775956B2 (de)
DE (1) DE69931178T8 (de)
NZ (1) NZ511119A (de)
WO (1) WO2000025805A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
CA2400948A1 (en) 2000-02-25 2001-08-30 Ludwig Institute For Cancer Research Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins
US7355019B2 (en) * 2000-06-06 2008-04-08 Sibtech, Inc. Cysteine-containing peptide tag for site-specific conjugation of proteins
WO2002004002A2 (de) * 2000-07-11 2002-01-17 Bayer Aktiengesellschaft Verwendung von stämmen des parapoxvirus ovis zur herstellung von antiviralen arzneimitteln und arzneimitteln gegen krebs
DE10122451A1 (de) * 2000-07-11 2002-04-04 Bayer Ag Verwendung von Stämmen des Parapoxvirus ovis zur Herstellung von antiviralen Arzneimitteln und Arzneimitteln gegen Krebs
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
JP2005500045A (ja) * 2001-07-12 2005-01-06 ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ リンパ管内皮細胞材料および方法
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
EP1442056A1 (de) * 2001-11-01 2004-08-04 The University of British Columbia Diagnostik und behandlung infektioser krankheiten mittels indel-differenzierter proteine
WO2004045531A2 (en) * 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection of cardiac myocardium
CN100577205C (zh) * 2002-12-17 2010-01-06 艾库里斯有限及两合公司 绵羊副痘病毒的重组蛋白和由其制备的药物组合物
EP2351769A3 (de) * 2002-12-17 2011-11-02 AiCuris GmbH & Co. KG Rekombinante Proteine des Parapoxivirus Ovis und pharmazeutische Zusammensetzungen daraus
JP2006517586A (ja) * 2003-02-04 2006-07-27 ラドウィグ インスティテュート フォー キャンサー リサーチ 幹細胞のｖｅｇｆ−ｂ及びｐｄｇｆ調節
US20050043235A1 (en) * 2003-06-12 2005-02-24 Kari Alitalo Use of VEGF-C or VEGF-D in reconstructive surgery
US20050032697A1 (en) * 2003-06-12 2005-02-10 Kari Alitalo Heparin binding VEGFR-3 ligands
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
JP2005110508A (ja) * 2003-10-02 2005-04-28 Nec Soft Ltd 血管内皮増殖因子受容体２型に対する特異的結合性を有するヘビ毒由来血管内皮増殖因子様タンパク質と用途
WO2005087177A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
ATE502956T1 (de) 2005-08-15 2011-04-15 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
TW200732347A (en) 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use
AU2013213745B2 (en) * 2005-10-06 2015-10-29 Trophogen, Inc. VEGF analogs and methods of use
PL2018184T3 (pl) 2006-05-17 2013-12-31 The Ludwig Institute For Cancer Res Przeciwciało Anty-VEGF-B do stosowania w leczeniu lub profilaktyce cukrzycy typu II lub zespołu metabolicznego
US8741839B2 (en) 2009-01-18 2014-06-03 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin
WO2011154308A1 (en) 2010-06-08 2011-12-15 Proyecto De Biomedicina Cima, S.L. New compositions and cell therapy methods for the treatment of cirrhosis
EP2431168B1 (de) 2010-09-20 2013-05-01 Bekaert Textiles N.V. Abdeckmaterial
AU2013263502B2 (en) * 2012-05-18 2018-02-08 Otago Innovation Limited Combination treatments and compositions for wound healing
RS58881B1 (sr) 2012-07-30 2019-08-30 Trophogen Inc Dugodelujući superagonisti glikoproteinskih hormona
US10457713B2 (en) 2012-07-30 2019-10-29 Trophogen, Inc. Glycoprotein hormone long-acting superagonists
NZ710658A (en) 2013-02-18 2019-12-20 Vegenics Pty Ltd Ligand binding molecules and uses thereof
AR098314A1 (es) 2013-11-05 2016-05-26 Trophogen Inc Superagonistas de acción prolongada de hormonas glicoproteicas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177401B1 (en) * 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
CA2247336C (en) * 1996-02-28 2008-06-17 Bayer Aktiengesellschaft Parapoxviruses containing foreign dna, their production and their use in vaccines
EP0904393A4 (de) * 1996-03-29 1999-09-08 Univ Otago Parapockenvirus-vektoren
DE19813774A1 (de) * 1998-03-27 1999-09-30 Max Planck Gesellschaft Parapockenvirus-kodierter vaskulärer Endothelzell Wachstumsfaktor (PPV-VEGF)

Also Published As

Publication number Publication date
WO2000025805A1 (en) 2000-05-11
JP2003517275A (ja) 2003-05-27
US20030211101A1 (en) 2003-11-13
AU1605300A (en) 2000-05-22
NZ511119A (en) 2004-04-30
EP1126863A4 (de) 2003-01-02
EP1126863A1 (de) 2001-08-29
DE69931178T8 (de) 2007-06-28
DE69931178T2 (de) 2007-02-22
ATE324902T1 (de) 2006-06-15
WO2000025805A8 (en) 2000-08-31
US6541008B1 (en) 2003-04-01
EP1126863B1 (de) 2006-05-03
AU775956B2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
DE69931178D1 (de) Ein dem vaskularen endothelen wachstumsfaktor verwandtes protein aus orf virus nz10 bindet und aktiviert den säuger vegf rezeptor-2
CY1119512T1 (el) Αντισωματα του υποδοχεα 1 της ιντερφερονης αλφα και οι χρησεις αυτων
DK0817648T3 (da) Antagonister mod vaskulære endotelcellevækstfaktorer
CY1107475T1 (el) Αναστολεις ρο-κινασης
DE60141409D1 (de) Homologe des nogo rezeptors
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
ATE407697T1 (de) Erythropoietin immunglobulin fusionsproteine
EP2287194A3 (de) Ephb4-bindende Antikörper zur Inhibierung von Angiogenese und Tumorwachstum
DE60108857D1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE363531T1 (de) Claudin polypeptide
ATE492266T1 (de) Farbverändernde mittel mit moringa extrakt
MX2021015651A (es) Proteinas de union a la proteina accesoria del receptor de interleucina-1 (il1rap).
DK1228097T3 (da) Antimikrobiel aktivitet af den förste kationiske humane lactoferrin-klynge
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
DE60319135D1 (de) Peptide, die die heparinbindungsdomäne von vegf und vegfr-2 binden
WO2001042284A3 (en) Protein comprising ig-like domain 4 of a vegf receptor mediates receptor dimerization, but not activation
ATE247130T1 (de) Inhibitoren für den urokinaserezeptor
ATE492564T1 (de) Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
ATE324906T1 (de) Verwendung von chimäres il6-il6r in huntingtonskrankheit
DE50014789D1 (de) Kombination von verbindungen, welche die biologischen wirkungen von tnf-alpha und cd95l hemmen, in einem arzneimittel
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
WO2002064621A3 (en) Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent
MX2023014037A (es) Proteinas de fusion activas renales y metodos de tratamiento que usan las mismas.
CO2023015999A2 (es) Proteínas de fusión activas renales y métodos de tratamiento que usan las mismas
NO982151L (no) Hemoregulatoriske forbindelser

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: WISE, M., LYN, DUNEDIN, NZ

Inventor name: MERCER, A., ANDREW, DUNEDIN, NZ

Inventor name: SAVORY, J., LOREEN, DUNEDIN, NZ

Inventor name: FLEMING, B., STEPHEN, DUNEDIN, NZ

Inventor name: STACKER, STEVEN A., ANGIOGENESIS LAB., PARKVIL, US

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1126863

Country of ref document: EP

Representative=s name: WINTER, BRANDL, FUERNISS, HUEBNER, ROESS, KAIS, DE